AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration

AbbVie has announced a major agreement with the U.S. government that could reshape drug pricing and pharmaceutical investment in the country. The company said it has entered into a three-year deal with President Donald Trump’s administration aimed at reducing prescription drug prices while significantly expanding its U.S.-based research, development, and manufacturing footprint.

As part of the agreement, AbbVie pledged to invest $100 billion in the United States over the next decade. This investment will support research and development initiatives, manufacturing expansion, and enhanced direct-to-patient access for several widely prescribed medicines. Drugs included in the initiative are Alphagan, Combigan, Humira, and Synthroid, which will be offered through the TrumpRx program, a platform designed to help cash-paying consumers purchase medications directly from pharmaceutical manufacturers’ websites.

In return, AbbVie will receive exemptions from tariffs and protection from future government-imposed pricing mandates for the duration of the three-year agreement. While AbbVie confirmed these key benefits, it noted that additional terms of the deal remain confidential.

The agreement comes as the Trump administration continues to pressure drugmakers to lower prescription drug costs in the United States. Americans often pay nearly three times more for medications compared to patients in other developed countries, a long-standing issue that has drawn political and public scrutiny. By encouraging direct-to-consumer sales and negotiated pricing, the administration aims to improve affordability, particularly for uninsured and cash-paying patients.

AbbVie is not alone in reaching such agreements. In December, the administration finalized similar pricing deals with other major pharmaceutical companies, including Roche, Merck, and Gilead. Those agreements focused on reducing prices for the Medicaid program and for consumers paying out of pocket.

However, the impact of TrumpRx may be limited for insured Americans. Most patients with health insurance pay fixed co-pays or co-insurance based on list prices, meaning they may not directly benefit from lower cash prices offered through manufacturer websites. Still, AbbVie’s commitment marks one of the largest domestic investment pledges tied to drug pricing reform, highlighting a growing shift in how pharmaceutical companies engage with U.S. healthcare policy and consumers.